Vaxxinity, Inc. Stock Price, News & Analysis

Vaxxinity, Inc. (Nasdaq: VAXX) announced that CEO Mei Mei Hu will participate in a fireside chat at the Jefferies Healthcare Conference on June 9, 2022, at 11:30 a.m. ET in New York. Investors can access a live webcast through the company’s Investor section on its website, with a replay available for 90 days afterward.

Vaxxinity is focused on developing synthetic, peptide-based immunotherapeutic vaccines aimed at treating chronic diseases and is committed to democratizing healthcare globally.

Vaxxinity, Inc. (Nasdaq: VAXX) announced its Q1 2022 financial results, reporting a net loss of $18.3 million ($0.15 per share), significantly improved from a loss of $32.0 million in Q1 2021. Cash and cash equivalents decreased to $124.8 million. Key developments include FDA Fast Track designation for its Alzheimer's vaccine candidate UB-311 and enrollment completion for its Parkinson's vaccine UB-312, with results anticipated in H2 2022. The company is also advancing its COVID-19 vaccine UB-612 through a Phase 3 trial.

Vaxxinity, Inc. (Nasdaq: VAXX) has announced that CEO Mei Mei Hu will participate in a fireside chat at the Bank of America Securities 2022 Healthcare Conference in Las Vegas on May 12, 2022, at 10:40 a.m. PT. A live webcast will be available under the Investor section of their website, with replays accessible for 90 days. Vaxxinity is focused on developing synthetic, peptide-based immunotherapeutic vaccines to treat chronic diseases such as Alzheimer’s and COVID-19. Their innovative technology aims to disrupt traditional treatments that are costly and complex.

Vaxxinity has received Fast Track designation from the FDA for UB-311, an anti-amyloid beta immunotherapeutic vaccine aimed at treating Alzheimer's disease. This designation emphasizes the promising potential of UB-311 in addressing significant unmet medical needs for patients suffering from Alzheimer's. The vaccine's safety profile is comparable to a placebo and shows robust antibody responses. The company plans to initiate a Phase 2b trial in late 2022, positioning UB-311 to lead a shift in Alzheimer's treatment.

Vaxxinity, Inc. (Nasdaq: VAXX) announced the completion of patient enrollment for Part B of its Phase 1 clinical trial of UB-312, aimed at treating Parkinson's disease and other related disorders. The trial targets pathological forms of alpha-synuclein and has yielded positive preliminary results indicating safety and immunogenicity in earlier trials. Funded by the Michael J. Fox Foundation, the study has enrolled 50 healthy volunteers and 20 Parkinson's patients, with full analysis expected in 2023.

Vaxxinity, Inc. (Nasdaq: VAXX) has partnered with the Coalition for Epidemic Preparedness Innovations (CEPI) to co-fund a pivotal Phase 3 trial for its COVID-19 vaccine candidate, UB-612. CEPI will provide $9.25 million to assess UB-612 as a heterologous booster for individuals previously vaccinated with authorized COVID-19 vaccines. Approximately 1,000 participants will be involved, with analysis results expected in the second half of 2022. The trial aims to contribute to flexible vaccination strategies and broaden access to effective COVID-19 vaccines, especially in low- and middle-income countries.

Vaxxinity, Inc. (Nasdaq: VAXX) has initiated a Phase 3 pivotal trial for its COVID-19 booster candidate UB-612, which aims to demonstrate non-inferiority against existing vaccines. The trial, involving participants aged 16 and older, is designed to evaluate UB-612's efficacy compared to mRNA, adenovirus vector, and inactivated virus vaccines. Vaxxinity anticipates a topline data readout in late 2022, with hopes of gaining conditional approval. Previous trials indicated UB-612 is well-tolerated and generates neutralizing antibodies, including against the Omicron variant.

Vaxxinity, Inc. (Nasdaq: VAXX) reported its Q4 and full-year 2021 financial results, highlighting a significant transformation following its IPO and strategic clinical advancements. Key developments include ongoing Phase 1 and Phase 3 trials for UB-312 and UB-612, with anticipated topline readouts in late 2022. Despite cash and equivalents reaching $144.9 million, Vaxxinity faced a net loss of $48.2 million for Q4 and $137.2 million for the year, reflecting increased R&D and G&A expenses primarily driven by stock-based compensation. The company aims to expand its clinical pipeline in the upcoming year.

Vaxxinity, Inc. (Nasdaq: VAXX) announced the retirement of Dr. Peter Powchik as its Executive Vice President of Research & Development, effective March 31, 2022. He will join Vaxxinity’s Board of Directors, increasing the board's size to seven. Praised for his significant contributions in drug development, Dr. Powchik's expertise is expected to enhance Vaxxinity's mission to innovate in chronic disease treatment through immunotherapeutic vaccines. The company aims to democratize healthcare with its peptide-based vaccine technology targeting various chronic conditions.